7 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Response Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists RDX-002, Placebo - Triglycerides, Weight Gain Trajectory | Phase 2 | Completed | Response Pharmaceuticals | 68 | 2024-09-27 | 2026-07-02 |
| Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine RDX-002 - Drug-induced Weight Gain | Phase 1 | Completed | Response Pharmaceuticals | 24 | 2023-05-16 | 2023-11-18 |
| Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus KD026, Placebo, Metformin - Type 2 Diabetes Mellitus | Phase 2 | Completed | Response Pharmaceuticals | 121 | 2015-04-01 | 2023-11-18 |
| A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes SLx-4090, Placebo, Metformin - Type 2 Diabetes | Phase 2 | Completed | Response Pharmaceuticals | 82 | 2009-04-01 | 2023-11-18 |
| Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia SLx-4090, Placebo, Statin - Hyperlipidemia | Phase 2 | Completed | Response Pharmaceuticals | 133 | 2009-01-01 | 2023-11-18 |
| Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease SLx-2101, Placebo - Raynaud's Disease | Phase 2 | Completed | Response Pharmaceuticals | 17 | 2007-06-01 | 2023-11-18 |
| Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides SLx-4090, Placebo - Hypertriglyceridemia | Phase 2 | Completed | Response Pharmaceuticals | 24 | 2007-05-01 | 2023-11-18 |
Diabetes Mellitus, Type 2 (2) · Body-Weight Trajectory (1) · Hypercholesterolemia (1) · Hyperlipidemias (1) · Hypertriglyceridemia (1) · Obesity (1) · Raynaud Disease (1)
6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (4) · Metformin (2) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)
United States (5) · Germany (2)
Grit Anderson, MD (1) · M Baumaker, MD (1) · Tricia Stamp, PhD, PA-C (1) · Trisha Stamp, PhD, PA-C (1)